FindTrial
Sign In

Study on the Prognosis of Neoadjuvant Chemoradiotherapy Response and Related Immune Infiltration and Gene Characteristics in Esophageal Squamous Cell Carcinoma

Study on the Related Immune Infiltration and Gene Characteristics of the Response to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120708
Enrollment
Unknown
Registered
2026-03-18
Start date
2022-02-21
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

Observation group:None

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who visited the hospital from January 1, 2002 to October 1, 2021, with ages ranging from 18 to 80 years old, who underwent radical esophagectomy after receiving neoadjuvant chemoradiotherapy, and were diagnosed with esophageal cancer pathologically.

Exclusion criteria

Exclusion criteria: Patients who did not undergo R0 resection; patients with missing follow-up information.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Secondary

MeasureTime frame
Disease-free survival;—

Countries

China

Contacts

Public ContactJianhua Fu

Sun Yat-Sen University Cancer Center

fujh@mail.sysu.edu.cn+86 20 8734 3403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026